Hande Sciences
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Chinese CDMO providing comprehensive small molecule development and manufacturing services from discovery to commercial scale.
Not specified - service provider
Technology Platform
Small molecule synthesis and process development platform with HPAPI capabilities, 120 reactors (50-8000L), and facilities meeting US/EU GMP standards.
Opportunities
Growing demand for Chinese CDMO services from both domestic biotechs and international companies seeking cost-effective manufacturing; specialized HPAPI capabilities address needs of targeted cancer therapies and other potent compounds.
Risk Factors
Intense competition in Chinese CDMO market from established players like WuXi; regulatory scrutiny of Chinese manufacturing facilities by Western agencies; potential geopolitical tensions affecting international partnerships.
Competitive Landscape
Competes with Chinese CDMOs like WuXi AppTec, Pharmaron, and Porton, plus multinationals with Chinese operations; differentiation through specialized HPAPI capabilities, modern GMP-compliant facility, and comprehensive service offering from discovery to commercialization.